eligibility_summary
Adults (≥18) with advanced SCLC (including EGFR-mutant NSCLC transformed to SCLC) progressing during/after platinum, any prior lines, measurable disease, ECOG 0–2, adequate marrow, liver, kidney, coagulation, pre-treatment biopsy (unless unsafe), able to consent/comply, contraception required. Exclude: leptomeningeal disease, other trials, major surgery <4 wks, interfering malignancy, pleural/pericardial effusion, high-risk conditions, pregnancy/breastfeeding. Treated brain mets allowed.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: MGC018, an antibody–drug conjugate (ADC) given IV (2.7 mg/kg q28d). Mechanism of action: a humanized anti–B7‑H3 (CD276) IgG1 that binds B7‑H3 on tumor cells, is internalized, and via a protease‑cleavable linker releases a duocarmycin DNA‑alkylating payload, causing DNA minor‑groove alkylation, DNA damage, and tumor cell death. Drug type: targeted cytotoxic immunotherapy (ADC). Targets/cells/pathways: B7‑H3–expressing cells prevalent in extensive‑stage small‑cell lung cancer (SCLC) and elements of the tumor microenvironment expressing B7‑H3, leverages the B7‑H3 immune checkpoint axis for selective delivery rather than checkpoint blockade, downstream impact is on DNA integrity/cell‑cycle/apoptosis pathways in tumor cells.